Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery DOI Creative Commons
L. R. Jackson,

Ann L. Erickson,

Kevin Camphausen

и другие.

Current Oncology, Год журнала: 2024, Номер 32(1), С. 16 - 16

Опубликована: Дек. 28, 2024

Glioblastoma (GBM) is a primary central nervous system malignancy with median survival of 15–20 months. The presence both intra- and intertumoral heterogeneity limits understanding biological mechanisms leading to tumor resistance, including immune escape. An attractive field research examine treatment resistance are signatures composed cluster differentiation (CD) markers cytokines. CD surface expressed on various cells throughout the body, often associated cells. Cytokines effector molecules system. Together, cytokines can serve as useful biomarkers reflect status in patients GBM. However, there gaps intricate interactions between GBM peripheral how these change standard immune-modulating treatments. key true nature through multi-omic analysis progression response. This review aims identify potential non-invasive blood-based that contribute an signature approaches, better involvement

Язык: Английский

Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives DOI Open Access
Ilaria Salvato, Antonio Marchini

Cancers, Год журнала: 2024, Номер 16(7), С. 1276 - 1276

Опубликована: Март 25, 2024

Despite decades of research and the best up-to-date treatments, grade 4 Glioblastoma (GBM) remains uniformly fatal with a patient median overall survival less than 2 years. Recent advances in immunotherapy have reignited interest utilizing immunological approaches to fight cancer. However, current immunotherapies so far not met anticipated expectations, achieving modest results their journey from bench bedside for treatment GBM. Understanding intrinsic features GBM is crucial importance development effective antitumoral strategies improve life expectancy conditions. In this review, we provide comprehensive overview distinctive characteristics that significantly influence conventional therapies immune-based approaches. Moreover, present an immunotherapeutic currently undergoing clinical evaluation treatment, specific emphasis on those advancing phase 3 studies. These encompass immune checkpoint inhibitors, adoptive T cell therapies, vaccination (i.e., RNA-, DNA-, peptide-based vaccines), virus-based Finally, explore novel innovative future prospects field

Язык: Английский

Процитировано

17

Systemic and local immunosuppression in glioblastoma and its prognostic significance DOI Creative Commons
Aleksei A. Stepanenko, Anastasiia O. Sosnovtseva, M. P. Valikhov

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Фев. 28, 2024

The effectiveness of tumor therapy, especially immunotherapy and oncolytic virotherapy, critically depends on the activity host immune cells. However, various local systemic mechanisms immunosuppression operate in cancer patients. Tumor-associated involves deregulation many components immunity, including a decrease number T lymphocytes (lymphopenia), an increase levels or ratios circulating tumor-infiltrating immunosuppressive subsets [e.g., macrophages, microglia, myeloid-derived suppressor cells (MDSCs), regulatory (Tregs)], as well defective functions antigen-presenting, helper effector cell due to altered expression soluble membrane proteins (receptors, costimulatory molecules, cytokines). In this review, we specifically focus data from patients with glioblastoma/glioma before standard chemoradiotherapy. We discuss glioblastoma-related at baseline prognostic significance different (lymphocytes, CD4+ CD8+ cells, Tregs, natural killer (NK) neutrophils, MDSCs, dendritic cells), neutrophil-to-lymphocyte ratio (NLR), landscape isocitrate dehydrogenase ( IDH )-mutant gliomas, proneural, classical mesenchymal molecular subtypes, highlight features surveillance brain. All attempts identify reliable marker glioblastoma tissue have led contradictory results, which can be explained, among other things, by unprecedented level spatial heterogeneity infiltrate significant phenotypic diversity (dys)functional states subpopulations. High NLR is one most repeatedly confirmed independent factors for shorter overall survival carcinoma, its combination markers response inflammation significantly improves accuracy prediction; however, more prospective studies are needed confirm prognostic/predictive power NLR. call inclusion dynamic assessment blood inflammatory (e.g., absolute/total lymphocyte count, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte immune-inflammation index, index) all neuro-oncology rigorous evaluation comparison their individual combinatorial relative superiority.

Язык: Английский

Процитировано

8

GBM immunotherapy: Exploring molecular and clinical frontiers DOI
Mrinal K. Ghosh,

Sunny Kumar,

Sabana Begam

и другие.

Life Sciences, Год журнала: 2024, Номер 356, С. 123018 - 123018

Опубликована: Авг. 28, 2024

Язык: Английский

Процитировано

4

Radiation-Induced Brain Injury with Special Reference to Astrocytes as a Therapeutic Target DOI Creative Commons
Caiping Wang,

Xingjuan Fan,

Yunwei Shi

и другие.

Journal of Integrative Neuroscience, Год журнала: 2025, Номер 24(3)

Опубликована: Март 21, 2025

Radiotherapy is one of the primary modalities for oncologic treatment and has been utilized at least once in over half newly diagnosed cancer patients. Cranial radiotherapy significantly enhanced long-term survival rates patients with brain tumors. However, radiation-induced injury, particularly hippocampal neuronal damage along impairment neurogenesis, inflammation, gliosis, adversely affects quality life these Astrocytes, a type glial cell that are abundant brain, play essential roles maintaining homeostasis function. Despite their importance, pathophysiological changes astrocytes induced by radiation have not thoroughly investigated, no systematic or comprehensive review addressing effects on related diseases conducted. In this paper, we current studies neurophysiological following exposure. We describe astrocytes, including astrogliosis, astrosenescence, associated cellular molecular mechanisms. Additionally, summarize impairments neurogenesis blood-brain barrier (BBB). Based research, propose may serve as potential therapeutic targets treating injury (RIBI) subsequent neurological neuropsychiatric disorders.

Язык: Английский

Процитировано

0

Pediatric brain tumor patients display altered immune activation and reduced lymphopoiesis at the onset of disease DOI Creative Commons
Marco Rosichini, Giada Del Baldo,

Carmen Dolores De Luca

и другие.

npj Precision Oncology, Год журнала: 2024, Номер 8(1)

Опубликована: Ноя. 20, 2024

Optimal immune function is crucial in preventing cancer development and growth for the success of anti-cancer therapies. Here, we characterized peripheral immunological status 83 steroids-naïve pediatric patients with central nervous system neoplasia at disease onset. Tumors were classified into low-grade gliomas (LGG), high-grade (HGG), medulloblastoma, other tumors. We revealed that glioma showed an altered lymphocyte pool. T-cells HGG shifted from naïve to effector memory phenotype. LGG exhibited T-cell expansion higher activation. Interestingly, displayed reduced thymic function. Furthermore, activated B-cells suboptimal B-cell formation. Our data demonstrate have lymphopoiesis onset, which could contribute systemic lymphopenia characterizing these patients. This study offers novel insights brain tumor may help designing more effective treatments.

Язык: Английский

Процитировано

0

Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors DOI Open Access
Parvin Pourmasoumi, Seyed Abdolvahab Banihashemian,

Farshid Zamani

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(23), С. 7449 - 7449

Опубликована: Дек. 6, 2024

Glioblastomas are highly invasive brain tumors among perilous diseases. They characterized by their fast proliferation and delayed detection that render them a significant focal point for medical research endeavors within the realm of cancer. Among glioblastomas,

Язык: Английский

Процитировано

0

Neoadjuvant Clinical Trials in Adults with Newly Diagnosed High-Grade Glioma: A Systematic Review DOI
Tiffany Juarez, Jaya M. Gill, Boris Minev

и другие.

Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер unknown, С. 104596 - 104596

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

0

Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery DOI Creative Commons
L. R. Jackson,

Ann L. Erickson,

Kevin Camphausen

и другие.

Current Oncology, Год журнала: 2024, Номер 32(1), С. 16 - 16

Опубликована: Дек. 28, 2024

Glioblastoma (GBM) is a primary central nervous system malignancy with median survival of 15–20 months. The presence both intra- and intertumoral heterogeneity limits understanding biological mechanisms leading to tumor resistance, including immune escape. An attractive field research examine treatment resistance are signatures composed cluster differentiation (CD) markers cytokines. CD surface expressed on various cells throughout the body, often associated cells. Cytokines effector molecules system. Together, cytokines can serve as useful biomarkers reflect status in patients GBM. However, there gaps intricate interactions between GBM peripheral how these change standard immune-modulating treatments. key true nature through multi-omic analysis progression response. This review aims identify potential non-invasive blood-based that contribute an signature approaches, better involvement

Язык: Английский

Процитировано

0